Legal entity
Every one of those 1 sits in a single category, regulation. Of the tracked stories, 1 of 1 also mention ASCENIV, the most common co-covered peer. They are less corroborated than the beat average, carrying 4 original sources each against 4.6 for the same window.
Last mentioned: Jul 12, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, regulation. Of the tracked stories, 1 of 1 also mention ASCENIV, the most common co-covered peer. They are less corroborated than the beat average, carrying 4 original sources each against 4.6 for the same window. At 7, the average consequence score sits above the same-window beat average of 6.5. ADMA Biologics, Inc. appears in 1 tracked Legal story from July 12, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 33 Legal stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering ADMA Biologics, Inc.. Shared-story counts are live from our verified record — not editorial picks.
BFA Law launches coordinated class actions against Microsoft, ADMA, Insulet, and Embecta over product-related misrepresentations, with lead plaintiff deadlines in August.
Source: stockhouse.com · stockhouse.com
ADMA Biologics, Inc. is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
